CBT
VRTX icon

Central Bank & Trust’s Vertex Pharmaceuticals VRTX Stock Holding History

Central Bank & Trust’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$253K Buy
+510
New +$226K 0.04% 171
2024
Q3 		– Sell
-40
Closed -$18.7K – 349
2024
Q2 		$18.7K Hold
40
– – ﹤0.01% 292
2024
Q1 		$16.7K Sell
40
-58
-59% -$24.5K ﹤0.01% 276
2023
Q4 		$39.9K Sell
98
-16
-14% -$5.91K 0.01% 253
2023
Q3 		$39.6K Hold
114
– – 0.01% 237
2023
Q2 		$40.1K Sell
114
-27
-19% -$9.1K 0.01% 233
2023
Q1 		$44.4K Buy
141
+109
+341% +$32.7K 0.01% 231
2022
Q4 		$9.24K Hold
32
– – ﹤0.01% 291
2022
Q3 		$9K Sell
32
-133
-81% -$38.3K ﹤0.01% 282
2022
Q2 		$46K Sell
165
-80
-33% -$21.4K 0.01% 228
2022
Q1 		$64K Buy
245
+165
+206% +$39.2K 0.01% 218
2021
Q4 		$18K Sell
80
-1,244
-94% -$242K ﹤0.01% 267
2021
Q3 		$240K Buy
1,324
+25
+2% +$4.88K 0.04% 152
2021
Q2 		$262K Buy
1,299
+56
+5% +$11.7K 0.04% 149
2021
Q1 		$267K Buy
1,243
+70
+6% +$15.4K 0.05% 144
2020
Q4 		$277K Buy
1,173
+702
+149% +$161K 0.05% 135
2020
Q3 		$128K Buy
471
+420
+824% +$116K 0.02% 162
2020
Q2 		$15K Hold
51
– – ﹤0.01% 214
2020
Q1 		$12K Buy
+51
New +$11.7K ﹤0.01% 220
2019
Q2 		– Sell
-24
Closed -$4K – 280
2019
Q1 		$4K Hold
24
– – ﹤0.01% 257
2018
Q4 		$4K Hold
24
– – ﹤0.01% 255
2018
Q3 		$5K Buy
+24
New +$4.27K ﹤0.01% 252
2016
Q2 		– Sell
-119
Closed -$9K – 345
2016
Q1 		$9K Hold
119
– – ﹤0.01% 278
2015
Q4 		$15K Buy
119
+85
+250% +$10.3K ﹤0.01% 261
2015
Q3 		$4K Hold
34
– – ﹤0.01% 351
2015
Q2 		$4K Buy
34
+7
+26% +$882 ﹤0.01% 338
2015
Q1 		$3K Buy
+27
New +$3.23K ﹤0.01% 313

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Central Bank & Trust's VRTX Position: Q2 2026 in Review

Central Bank & Trust opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 510 shares worth $253K. The stake represents 0.04% of the portfolio and ranks #171 among its holdings. This is a return to the name: Central Bank & Trust previously reported a position in VRTX as recently as Q2 2024.

Central Bank & Trust first reported a position in VRTX in Q1 2015 and has held it in 27 quarters since. The position peaked at $277K in Q4 2020. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Central Bank & Trust held 510 shares of Vertex Pharmaceuticals worth $253K as of Q2 2026.
  • Vertex Pharmaceuticals was a new Central Bank & Trust position in Q2 2026.
  • Vertex Pharmaceuticals made up 0.04% of Central Bank & Trust's portfolio in Q2 2026, its #171 holding.
  • Central Bank & Trust first reported a position in Vertex Pharmaceuticals in Q1 2015 and has held it in 27 quarters since.
  • Central Bank & Trust's Vertex Pharmaceuticals position peaked at $277K in Q4 2020.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Central Bank & Trust's 13F filing for Q2 2026, filed 17 Jul 2026.